Print this page
-
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements.
Protocol: 111906Principal Investigator:
- Scott Moerdler M.D. (Rutgers University)
Applicable Disease Sites: Any Site -
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL, Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy.
Protocol: 111911Principal Investigator:
- Marissa Botwinick MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Any Site -
A Phase II Study of TAS-102, Irinotecan and Bevacizumab in Pretreated Metastatic Colorectal Cancer.
Protocol: 071914Principal Investigator:
- Patrick Boland (Rutgers University)
Applicable Disease Sites: Colon -
A Phase 3 Randomized Study of Selumetinib versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma.
Protocol: 111914Principal Investigator:
- Scott Moerdler M.D. (Rutgers University)
Applicable Disease Sites: Brain and Nervous System -
A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies.
Protocol: 052002Principal Investigator:
- Salma Jabbour M.D. (Rutgers University)
Applicable Disease Sites: Liver
Any Site
Other Digestive Organ -
Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin.
Protocol: 102003Principal Investigator:
- Eugenia Girda Assistant Professor GYN (Rutgers University)
Applicable Disease Sites: Any Site